# A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct02716116/  
OnCo record `nct02716116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TAK-788 in non-small-cell lung cancer, run by Takeda, active and no longer recruiting.

## Summary

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT02716116 by Takeda, with 334 participants enrolled, started 2016-06-16 and due to reach its primary completion in 2026-10-31. Interventions recorded: TAK-788.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02716116
- Phase: 1/2
- Setting: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
- Sponsor: Takeda
- Enrolled: 334

## Sources

- ClinicalTrials.gov NCT02716116: https://clinicaltrials.gov/study/NCT02716116

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct02716116.json